165 related articles for article (PubMed ID: 24013390)
1. Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.
Song X; Kim SY; Lee YJ
PLoS One; 2013; 8(8):e73654. PubMed ID: 24013390
[TBL] [Abstract][Full Text] [Related]
2. The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer.
Song X; Kim SY; Lee YJ
Mol Cancer Res; 2012 Dec; 10(12):1567-79. PubMed ID: 23051936
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells.
Song X; Kim SY; Zhou Z; Lagasse E; Kwon YT; Lee YJ
Cell Death Dis; 2013 Apr; 4(4):e577. PubMed ID: 23559011
[TBL] [Abstract][Full Text] [Related]
4. Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells.
Kim SY; Lee DH; Song X; Bartlett DL; Kwon YT; Lee YJ
Apoptosis; 2014 Nov; 19(11):1603-15. PubMed ID: 25156145
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells.
Song X; Kim HC; Kim SY; Basse P; Park BH; Lee BC; Lee YJ
J Cell Biochem; 2012 May; 113(5):1547-58. PubMed ID: 22174016
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
7. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.
Kim SY; Song X; Zhang L; Bartlett DL; Lee YJ
Biochem Pharmacol; 2014 Mar; 88(2):178-88. PubMed ID: 24486574
[TBL] [Abstract][Full Text] [Related]
8. Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.
Zhang XL; Hu AB; Cui SZ; Wei HB
World J Gastroenterol; 2012 Feb; 18(7):646-53. PubMed ID: 22363135
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Timme CR; Gruidl M; Yeatman TJ
Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
[TBL] [Abstract][Full Text] [Related]
10. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
Griffiths GJ; Koh MY; Brunton VG; Cawthorne C; Reeves NA; Greaves M; Tilby MJ; Pearson DG; Ottley CJ; Workman P; Frame MC; Dive C
J Biol Chem; 2004 Oct; 279(44):46113-21. PubMed ID: 15326164
[TBL] [Abstract][Full Text] [Related]
11. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
12. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
14. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Mol Cancer Ther; 2004 Feb; 3(2):169-78. PubMed ID: 14985457
[TBL] [Abstract][Full Text] [Related]
15. Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells.
Yoo J; Lee YJ
J Cell Biochem; 2008 Jan; 103(1):98-109. PubMed ID: 17520700
[TBL] [Abstract][Full Text] [Related]
16. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
Nannizzi S; Veal GJ; Giovannetti E; Mey V; Ricciardi S; Ottley CJ; Del Tacca M; Danesi R
Cancer Chemother Pharmacol; 2010 Aug; 66(3):547-58. PubMed ID: 20020129
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.
Jani TS; DeVecchio J; Mazumdar T; Agyeman A; Houghton JA
J Biol Chem; 2010 Jun; 285(25):19162-72. PubMed ID: 20424169
[TBL] [Abstract][Full Text] [Related]
20. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
